Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Comparative analysis of the cost-effectiveness and implementation of lung cancer screening with LDCT in the US and EU

Principal Investigator
Name
Tanya Rajabi
Degrees
B.S.
Institution
Semmelweis University
Position Title
Visiting Scholar
Email
About this CDAS Project
Study
NLST (Learn more about this study)
Project ID
NLST-968
Initial CDAS Request Approval
Oct 11, 2022
Title
Comparative analysis of the cost-effectiveness and implementation of lung cancer screening with LDCT in the US and EU
Summary
Trials have proven that LDCT screening for lung cancer can reduce lung cancer mortality. Yet, questions remain on routine screening's cost-effectiveness and best implementation practices. The EU guidelines and processes for screening vary from those in the US. Thus, we believe that conducting a comprehensive comparative analysis of lung cancer LDCT screening strategies between the US and EU would provide insight on methods for improving its cost-effectiveness and implementation in both jurisdictions.
More specifically, a Markov cohort model depicting patient screening pathways and assessing cost-effectiveness has been created at Semmelweis University. We propose to update this model with the data from the NLST. Doing so will allow for the comparison of the implementation and cost-effectiveness of screening strategies between the US and EU.
Aims

1. Assess the cost-effectiveness of various lung cancer screening strategies.
2. Compare cost-effectiveness of strategies employed by the US and EU to identify both clinically efficient and cost-effective screening practices.

Collaborators

Zoltan Voko (MD, MSc, PhD, DSC), Semmelweis University Center for Health Technology Assessment
Balazs Nagy (MSc, PhD, DrHabil), Semmelweis University Center for Health Technology Assessment